Akrotome Imaging, Inc. is a Delaware C Corporation with offices in Ohio, Indiana, and California. Founded in 2008, the company focuses on translating cancer-targeted molecular probes into improved surgical and diagnostic approaches. Their technology, called FIRE, enables surgeons to accurately distinguish cancer tissue from healthy tissue, leading to enhanced surgical guidance and therapeutic monitoring. Akrotome Imaging aims to bring their innovative solutions to the clinical market efficiently and with minimal regulatory overhead, ultimately improving patient outcomes and healthcare economics.